{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:55:32Z","timestamp":1791327332963,"version":"4.3.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jtct.2024.05.009","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:25:44Z","timestamp":1715473544000},"page":"794-807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Improved Outcome of Allogeneic Transplantation in Older Patients Treated for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Reduced Duration of Immune Suppression"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5408-5298","authenticated-orcid":false,"given":"Linde M.","family":"Morsink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin L.E.","family":"Hazenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goda","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco R.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouschka","family":"Biswana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9864-5816","authenticated-orcid":false,"given":"Mar","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde A.M.","family":"Kooistra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5016-5792","authenticated-orcid":false,"given":"Laura B.","family":"Bungener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kees","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre B.","family":"Mulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.jtct.2024.05.009_bib0001","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2024.05.009_bib0002","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.009_bib0003","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"17","key":"10.1016\/j.jtct.2024.05.009_bib0004","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jtct.2024.05.009_bib0005","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jtct.2024.05.009_bib0006","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2024.05.009_bib0007","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.bbmt.2020.07.037","article-title":"Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide","volume":"26","author":"DeZern","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.05.009_bib0008","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.bbmt.2018.01.011","article-title":"Shortened-duration tacrolimus after nonmyeloablative, HLA-haploidentical bone marrow transplantation","volume":"24","author":"Kasamon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.05.009_bib0009","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.jtct.2024.05.009_bib0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.05.009_bib0011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.leukres.2019.03.004","article-title":"Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: a single center experience of 355 consecutive patients","volume":"80","author":"Hilberink","year":"2019","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.jtct.2024.05.009_bib0012","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.05.009_bib0013","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.009_bib0014","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.05.009_bib0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2024.05.009_bib0016","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.009_bib0017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2024.05.009_bib0018","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2024.05.009_bib0019","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2024.05.009_bib0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.009_bib0021","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2024.05.009_bib0022","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","article-title":"Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia","volume":"33","author":"Pollyea","year":"2019","journal-title":"Leukemia"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2024.05.009_bib0023","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1200\/JCO.2020.38.15_suppl.7501","article-title":"Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML)","volume":"38","author":"Dinardo","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2024.05.009_bib0024","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2024.05.009_bib0025","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/S2352-3026(15)00148-9","article-title":"Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis","volume":"2","author":"Versluis","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.009_bib0026","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/asheducation-2014.1.21","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults","volume":"2014","author":"Sorror","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"35","key":"10.1016\/j.jtct.2024.05.009_bib0027","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2024.05.009_bib0028","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","article-title":"Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60","volume":"57","author":"Pollyea","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2024.05.009_bib0029","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.bbmt.2015.10.019","article-title":"Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2024.05.009_bib0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","article-title":"Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT","volume":"13","author":"Sanz","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2024.05.009_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.07.021","article-title":"Post-transplantation cyclophosphamide versus tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation","volume":"28","author":"Mehta","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2024.05.009_bib0032","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41409-020-01144-2","article-title":"Incorporation of posttransplant cyclophosphamide as part of standard immunoprophylaxis for all allogeneic transplants: a retrospective, single institution study","volume":"56","author":"Cooper","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.05.009_bib0033","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.jtct.2024.05.009_bib0034","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2024.05.009_bib0035","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dulery","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2024.05.009_bib0036","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","article-title":"Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ciurea","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jtct.2024.05.009_bib0037","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jtct.2024.05.009_bib0038","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.jtct.2024.05.009_bib0039","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724004068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T15:31:29Z","timestamp":1723217489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724004068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2666636724004068"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.05.009","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved Outcome of Allogeneic Transplantation in Older Patients Treated for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Reduced Duration of Immune Suppression","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}